Co-promotion

Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, March 18, 2024
Research, Clobetasol, Inflammation, NDA, Co-promotion, Clinical trial, Optometry, FDA, Vision Source, Pharmaceutical industry

NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company, today announced its financial and operating results for the fourth quarter and full-year ended December 31, 2023.

Key Points: 
  • For the fourth quarter of 2023, net loss was approximately $8.0 million, or $0.18 per share.
  • Research and development expenses totaled approximately $4.1 million for the fourth quarter of 2023, compared to $2.2 million for the fourth quarter of 2022, an increase of approximately 84.6%.
  • For the fourth quarter of 2023, general and administrative expenses were approximately $3.4 million, compared to $3.2 million for the fourth quarter of 2022, an increase of approximately 7.3%.
  • Total operating expenses for the fourth quarter of 2023 were approximately $7.5 million, compared to approximately $5.4 million for the fourth quarter of 2022.

NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results

Retrieved on: 
Tuesday, March 26, 2024
Biotechnology, Pharmaceutical, Optical, Health, Research and development, PIN, Growth, NBY, G&A, Co-promotion, Amazon (company), OTC, Marketing, NovaBay Pharmaceuticals, Pharmaceutical industry

(NYSE American: NBY) reports financial results for the three and 12 months ended December 31, 2023 and provides a business update.

Key Points: 
  • (NYSE American: NBY) reports financial results for the three and 12 months ended December 31, 2023 and provides a business update.
  • Net product revenue for the fourth quarter of 2023 included $2.8 million from the eyecare and wound care segment, and $0.9 million from the skincare segment.
  • Gross margin on net product revenue for the fourth quarter of 2023 was 49%, compared with 48% for the fourth quarter of 2022.
  • Research & development (R&D) expenses also decreased for the fourth quarter of 2023 to $4 thousand, versus $66 thousand for the prior-year period.

Numab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop Multi-specific Antibody NM49 for Treatment of Cancer

Retrieved on: 
Wednesday, February 14, 2024
Therapy, Neoplasm, Senior, Cancer, Discovery, Co-promotion, Patient, CMC, Partnership, Pharmaceutical industry

HORGEN, Switzerland, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Numab Therapeutics AG (“Numab”) and Ono Pharmaceutical Co., Ltd. (“Ono”) today announced a global research, development and commercialization collaboration for NM49, a multi-specific antibody designed to activate tumor associated macrophage phagocytosis for the treatment of cancers and identified through Numab’s proprietary discovery and engineering technology platform.

Key Points: 
  • HORGEN, Switzerland, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Numab Therapeutics AG (“Numab”) and Ono Pharmaceutical Co., Ltd. (“Ono”) today announced a global research, development and commercialization collaboration for NM49, a multi-specific antibody designed to activate tumor associated macrophage phagocytosis for the treatment of cancers and identified through Numab’s proprietary discovery and engineering technology platform.
  • Under the terms of the agreement, Ono has obtained an option to in-license NM49 from Numab for global development and commercialization, with Numab retaining an option to co-develop and commercialize in the United States.
  • “This important partnership marks our third collaboration with Ono and the first one where Numab has the option to co-develop and commercialize in the United States.
  • We are thrilled to continue working with Ono on developing new high impact multi-specific therapeutics for cancer patients,” said David Urech, Ph.D., Founder and Chief Executive Officer of Numab Therapeutics.

LEQEMBI® to be launched in Japan for Alzheimer's disease on December 20

Retrieved on: 
Wednesday, December 13, 2023
Ministry of Health (Kuwait), Ministry, Brain, Risk management, Amyloid-related imaging abnormalities, Disease, Risk, History, Patient, CET, Intraparenchymal hemorrhage, Eisai, MCI, Alzheimer's disease, Marketing, Horseshoe kidney, Co-promotion, Ageing, ARIA, Hypersensitivity, NHI, HIV disease progression rates, Lecanemab, Medical device, Pharmaceutical industry, Residential care, Biogen, Health

LEQEMBI obtained manufacturing and marketing approval for the indication of slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD) in Japan on September 25, 2023.

Key Points: 
  • LEQEMBI obtained manufacturing and marketing approval for the indication of slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD) in Japan on September 25, 2023.
  • The launch, planned for December 20, will make Japan the second country to have the product on the market, following the U.S.
    "This is a great Christmas present!
  • Alzheimer's disease patients in Japan will now have access to the first disease modifying treatment.
  • This gives hope for the large aging population in Japan with a great need for new treatment options," says Gunilla Osswald, CEO of BioArctic.

LEQEMBI® to be launched in Japan for Alzheimer's disease on December 20

Retrieved on: 
Wednesday, December 13, 2023
Ministry of Health (Kuwait), Ministry, Brain, Risk management, Amyloid-related imaging abnormalities, Disease, Risk, History, Patient, CET, Intraparenchymal hemorrhage, Eisai, MCI, Alzheimer's disease, Marketing, Horseshoe kidney, Co-promotion, Ageing, ARIA, Hypersensitivity, NHI, HIV disease progression rates, Lecanemab, Medical device, Pharmaceutical industry, Residential care, Biogen, Health

LEQEMBI obtained manufacturing and marketing approval for the indication of slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD) in Japan on September 25, 2023.

Key Points: 
  • LEQEMBI obtained manufacturing and marketing approval for the indication of slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD) in Japan on September 25, 2023.
  • The launch, planned for December 20, will make Japan the second country to have the product on the market, following the U.S.
    "This is a great Christmas present!
  • Alzheimer's disease patients in Japan will now have access to the first disease modifying treatment.
  • This gives hope for the large aging population in Japan with a great need for new treatment options," says Gunilla Osswald, CEO of BioArctic.

Lecanemab winner in two categories at The Scrip Awards 2023

Retrieved on: 
Monday, November 20, 2023
Research, Pathology, Clinical trial, Patient, CET, Eisai, Alzheimer's disease, Co-promotion, Scrip, Boxed, HIV disease progression rates, Pharmaceutical industry, Biogen

STOCKHOLM, Nov. 20, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) invention lecanemab (LEQEMBI®), partnered with Eisai, was awarded the Best New Drug and the award for the Clinical Advance of the Year at the Scrip Awards 2023.

Key Points: 
  • STOCKHOLM, Nov. 20, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) invention lecanemab (LEQEMBI®), partnered with Eisai, was awarded the Best New Drug and the award for the Clinical Advance of the Year at the Scrip Awards 2023.
  • The Scrip Awards celebrate the best innovations and achievements of the international biopharma industry.
  • It was awarded for the success of the Phase 3 Clarity AD study of lecanemab.
  • The information was released for public disclosure, through the agency of the contact persons below, on November 20, 2023, at 08.30 a.m. CET.

Lecanemab winner in two categories at The Scrip Awards 2023

Retrieved on: 
Monday, November 20, 2023
Research, Pathology, Clinical trial, Patient, CET, Eisai, Alzheimer's disease, Co-promotion, Scrip, Boxed, HIV disease progression rates, Pharmaceutical industry, Biogen

STOCKHOLM, Nov. 20, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) invention lecanemab (LEQEMBI®), partnered with Eisai, was awarded the Best New Drug and the award for the Clinical Advance of the Year at the Scrip Awards 2023.

Key Points: 
  • STOCKHOLM, Nov. 20, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) invention lecanemab (LEQEMBI®), partnered with Eisai, was awarded the Best New Drug and the award for the Clinical Advance of the Year at the Scrip Awards 2023.
  • The Scrip Awards celebrate the best innovations and achievements of the international biopharma industry.
  • It was awarded for the success of the Phase 3 Clarity AD study of lecanemab.
  • The information was released for public disclosure, through the agency of the contact persons below, on November 20, 2023, at 08.30 a.m. CET.

Update relating to LEQEMBI® from Eisai's investor presentation of their quarterly report published today

Retrieved on: 
Tuesday, November 7, 2023
AD, Alzheimer's disease, Neurology, Co-promotion, IDN, CET, Patient, EU, Arms industry, Pharmaceutical industry, Biogen, Eisai

BioArctic has the right to high single digit royalty on global sales of LEQEMBI.

Key Points: 
  • BioArctic has the right to high single digit royalty on global sales of LEQEMBI.
  • BioArctic's complete interim report for the third quarter 2023 will be published on November 8 at 08:00 CET.
  • This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation.
  • The information was released for public disclosure, through the agency of the contact persons below, on November 7, 2023, at 09:15 a.m. CET.

Update relating to LEQEMBI® from Eisai's investor presentation of their quarterly report published today

Retrieved on: 
Tuesday, November 7, 2023
AD, Alzheimer's disease, Neurology, Co-promotion, IDN, CET, Patient, EU, Arms industry, Pharmaceutical industry, Biogen, Eisai

BioArctic has the right to high single digit royalty on global sales of LEQEMBI.

Key Points: 
  • BioArctic has the right to high single digit royalty on global sales of LEQEMBI.
  • BioArctic's complete interim report for the third quarter 2023 will be published on November 8 at 08:00 CET.
  • This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation.
  • The information was released for public disclosure, through the agency of the contact persons below, on November 7, 2023, at 09:15 a.m. CET.

LEQEMBI (lecanemab-Irmb) Named One of Time's Best Inventions of 2023

Retrieved on: 
Wednesday, October 25, 2023
Lecanemab, Alzheimer's disease, BEST, AD, Biogen, Health care, TIME, Pathology, Co-promotion, HIV disease progression rates, Dementia, Eisai, Disease, AI, Patient, Pharmaceutical industry

TOKYO, Oct 25, 2023 - (JCN Newswire) - Eisai Co. Ltd. announced today that TIME has selected Alzheimer's disease (AD) treatment LEQEMBI (lecanemab-irmb) as one of THE BEST INVENTIONS of 2023 in the Medical Care category.

Key Points: 
  • TOKYO, Oct 25, 2023 - (JCN Newswire) - Eisai Co. Ltd. announced today that TIME has selected Alzheimer's disease (AD) treatment LEQEMBI (lecanemab-irmb) as one of THE BEST INVENTIONS of 2023 in the Medical Care category.
  • TIME's annual list of THE BEST INVENTIONS features "200 extraordinary innovations changing lives."
  • TIME then evaluated each contender on a number of key factors, including originality, efficacy, ambition, and impact.
  • We will deliver LEQEMBI to the people with early AD who need it and their families, and aim to continue creating impact on global issues surrounding dementia.